{
    "data": [
        {
            "id": "4512486",
            "title": "SiriusPoint signals $389M MGA asset sales and targets 12%–15% ROE amid double-digit insurance growth",
            "description": "<html><body><p>Earnings Call Insights: SiriusPoint Ltd. (SPNT) Q3 2025</p>\n<h3>Management View</h3>\n<ul>\n<li>CEO Scott Egan emphasized the quarter as \"another successful quarter of delivery for SiriusPoint,\" highlighting a \"strong underwriting performance, deliberately targeted growth, the announcement of 2 MGA disposals,\" and an \"upgrade to positive outlook from S&amp;P.\" Egan stated, \"Our core combined ratio of 89.1% delivered an 11% increase in underwriting income versus last year, aided in part by no catastrophe losses in the quarter. We achieved a strong operating return on equity of 17.9%, significantly ahead of our across-the-cycle 12% to 15% target range.\"</li>\n<li>Egan announced agreements for the sale of SiriusPoint's \"100% stake in Armada and our 49% stake in Arcadian for combined total proceeds of $389 million, valuing them together at around 15x EBITDA.\" He noted, \"Upon closure of these deals, over $200 million of off-balance sheet value will be recognized in our book value, representing a per share increase of approximately $1.75.\"</li>\n<li>Egan also introduced a new CEO for IMG, stating, \"We are excited about the future of IMG and announced last week the appointment of a new CEO, Will Nihan, who joins us from Travelex.\"</li>\n<li>CFO James McKinney reported, \"At 89.1%, the core combined ratio is strong and broadly in line with the previous year. The combination of higher premiums, a strong core attritional loss ratio, lower expense ratio and no catastrophe losses produced core underwriting income of $70 million. This is an 11% increase from the third quarter of 2024 and our 12th consecutive quarter of positive income.\"</li>\n</ul>\n<h3>Outlook</h3>\n<ul>\n<li>Management reaffirmed the commitment to a long-term ROE across the cycle target of 12% to 15% following the MGA disposals.</li>\n<li>Egan stated, \"We reaffirm our commitment to a long-term ROE across the cycle target of 12% to 15% post these disposals.\"</li>\n<li>McKinney reiterated, \"For the full year, we remain comfortable with our previously stated expense ratio expectation of 6.5% to 7%.\"</li>\n<li>There was no explicit change to guidance language from the previous quarter, but management highlighted an expectation that \"fourth quarter premiums to be more in line with the growth produced on a year-to-date basis.\"</li>\n</ul>\n<h3>Financial Results</h3>\n<ul>\n<li>Gross premiums written grew 26% year-over-year in the quarter, marking the sixth consecutive quarter with double-digit growth, driven by the Insurance &amp; Services segment, particularly Accident &amp; Health, Surety, and Property.</li>\n<li>The core combined ratio was 89.1%. Operating net income was $85 million, increasing by 41% to $0.72 per share. Net income for the quarter was $87 million, compared to $5 million last year.</li>\n<li>Net service fee income increased 47% to $10 million. Net investment income was $73 million for the quarter.</li>\n<li>Common shareholders' equity increased $273 million to $2 billion. Diluted book value per share ex AOCI grew 13% or $1.83 to $16.47.</li>\n<li>The Insurance &amp; Services segment achieved a combined ratio of 90.1%. Accident &amp; Health premiums grew 24% year-to-date and now account for 45% of the segment's gross written premium.</li>\n<li>The Reinsurance segment saw gross written premium decrease by 2% to $310 million, with a combined ratio for the quarter of 87.9%.</li>\n</ul>\n<h3>Q&amp;A</h3>\n<ul>\n<li>Michael Phillips, Oppenheimer &amp; Co. Inc.: Questioned potential for further reduction in attritional accident year loss ratio and the sustainability of insurance growth. CEO Egan responded, \"I wouldn't expect any material movements, if I'm honest with you, as we sort of look out and over. Our ambition is always to reduce it, obviously, all of our ratios. But obviously, we have to take into account the environment as well.\"</li>\n<li>Phillips also asked about anomalies in A&amp;H or Surety that led to significant growth. Egan stated there were \"not anomalies\" but wins of new relationships, and McKinney explained, \"It's been a pipeline that has been growing and the strength of our relationships have been growing that have enabled what we've seen from a quarter growth perspective.\"</li>\n</ul>\n<h3>Sentiment Analysis</h3>\n<ul>\n<li>Analyst tone was positive, with Phillips congratulating the team and expressing appreciation for new disclosures and operational transparency.</li>\n<li>Management tone was confident and focused during prepared remarks and remained measured and transparent in Q&amp;A, with Egan emphasizing, \"Our ambition is always to reduce...all of our ratios,\" and McKinney reinforcing returns-focused discipline.</li>\n<li>Compared to the previous quarter, sentiment remained positive and constructive, with both analysts and management expressing confidence in the company's trajectory and risk management approach.</li>\n</ul>\n<h3>Quarter-over-Quarter Comparison</h3>\n<ul>\n<li>The current quarter maintained a strong focus on underwriting discipline, risk management, and capital efficiency, building on themes from the previous quarter.</li>\n<li>Guidance language regarding ROE and expense targets remained consistent, while the announcement of $389 million in MGA asset sales and recognition of $200 million in off-balance sheet value represented a significant new development.</li>\n<li>Double-digit growth in gross premiums written accelerated from 10% in Q2 to 26% in Q3, with the Accident &amp; Health and Surety lines highlighted as key growth drivers.</li>\n<li>Analysts continued to focus on underwriting quality, premium growth, and risk selection, similar to the prior quarter.</li>\n<li>Management confidence remained strong, with a continued emphasis on prudent capital allocation and risk-adjusted returns.</li>\n</ul>\n<h3>Risks and Concerns</h3>\n<ul>\n<li>Management highlighted the continued impact of catastrophe losses, noting that \"catastrophe losses are over $50 million higher than prior year.\"</li>\n<li>The company remains cautious with new MGA partners, reserving above pricing projections to account for limited performance experience.</li>\n<li>In Property and Aviation reinsurance, management described a cautious approach, with growth and capital allocation dependent on rate adequacy and market conditions.</li>\n<li>Egan noted, \"Our priority is the bottom line over top line. If conditions change, we will not be afraid to take decisive action to ensure appropriate underwriting margins.\"</li>\n</ul>\n<h3>Final Takeaway</h3>\n<p>SiriusPoint reported a quarter marked by strong underwriting results, robust premium growth particularly in Insurance &amp; Services, and significant progress in portfolio rationalization with the announced sale of Armada and Arcadian. Management reaffirmed its commitment to disciplined underwriting, capital allocation, and a 12% to 15% ROE target. The company remains focused on optimizing risk and returns, while maintaining a cautious stance on new relationships and market exposures, setting the stage for continued momentum into the final quarter of the year.</p>\n<p><a href=\"https://seekingalpha.com/symbol/spnt/earnings/transcripts\">Read the full Earnings Call Transcript</a></p>\n</body></html>",
            "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
            "link": "https://seekingalpha.com/news/4512486-siriuspoint-signals-389m-mga-asset-sales-and-targets-12-percent-15-percent-roe-amid-double",
            "pub_date": "2025-11-01 00:40:56",
            "source": "seekalpha",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "4512487",
            "title": "Mapfre SA reports 9M results",
            "description": "<html><body><ul><li>Mapfre SA <a href=\"https://static.seekingalpha.com/uploads/sa_presentations/392/116392/original.pdf\" target=\"_blank\">press release</a>  (MPFRF): 9M net financial income of €529.1M</li></ul>\n</body></html>",
            "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
            "link": "https://seekingalpha.com/news/4512487-mapfre-sa-reports-9m-results",
            "pub_date": "2025-11-01 00:40:56",
            "source": "seekalpha",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "4512484",
            "title": "Mitsubishi Chemical Group Corporation reports Q2 results",
            "description": "<html><body><ul>\n<li>Mitsubishi Chemical Group Corporation <a href=\"https://www.mcgc.com/english/ir/pdf/02461/02715.pdf\" rel=\"nofollow\" target=\"_blank\">press release</a>  (MTLHY): Q2  Net Income of ¥106.50B.</li>\n<li>Revenue of ¥918.4B.</li>\n</ul>\n</body></html>",
            "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
            "link": "https://seekingalpha.com/news/4512484-mitsubishi-chemical-group-corporation-reports-q2-results",
            "pub_date": "2025-11-01 00:35:56",
            "source": "seekalpha",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "4512482",
            "title": "Loomis AB (publ) Non-GAAP EPS of SEK 7.77, revenue of SEK 7.64B",
            "description": "<html><body><ul>\n<li>Loomis AB (publ) <a href=\"https://seekingalpha.com/pr/20287824-loomis-interim-report-january-september-2025\">press release</a>  (LOIMF): Q3  Non-GAAP EPS of SEK 7.77.</li>\n<li>Revenue of SEK 7.64B.</li>\n</ul>\n</body></html>",
            "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
            "link": "https://seekingalpha.com/news/4512482-loomis-ab-publ-non-gaap-eps-of-sek-777-revenue-of-sek-764b",
            "pub_date": "2025-11-01 00:30:58",
            "source": "seekalpha",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "4512469",
            "title": "Dayforce holders should vote in favor of sale to Thoma Bravo, ISS says",
            "description": "<html><body><p>Dayforce (<span class=\"ticker-hover-wrapper\"><a href=\"https://seekingalpha.com/symbol/DAY\" title=\"Dayforce Inc.\">DAY</a></span>) shareholders should vote in favor of the company's $70/share sale to Thoma Bravo, proxy adviser ISS recommended. Dayforce <span style=\"color: #008000;\">ticked higher by 0.5%.</span></p>\n<p>\"It appears that there was a sufficient level of price discovery during the sale process, and there is no reason to conclude that there would be a better offer available if this transaction breaks,\" ISS wrote in its recommendation, according to a copy viewed by Seeking Alpha. </p>\n<p>The recommendation comes after T. Rowe Price Associates, one of Dayforce's (NYSE:<a href=\"https://seekingalpha.com/symbol/DAY#hasComeFromMpArticle=false#source=section%3Amain_content%7Cbutton%3Abody_link%7Cfirst_level_url%3Anews\" title=\"Dayforce Inc.\">DAY</a>) largest shareholders, earlier this month said it planned to <a href=\"https://seekingalpha.com/news/4502604-dayforces-one-of-the-largest-investors-t-rowe-price-plans-to-vote-against-thoma-bravo-deal\" target=\"_blank\" title=\" vote against the transaction \"> vote against the transaction </a>due to \"underwhelming\" valuation the company was receiving in a sale.</p>\n<p>Dayforce <a href=\"https://seekingalpha.com/news/4487847-dayforce-to-go-private-in-123-billion-deal-with-thoma-bravo#hasComeFromMpArticle=false#source=section%3Amain_content%7Cbutton%3Abody_link%7Cfirst_level_url%3Anews\" rel=\"noopener\" target=\"_blank\" title=\"announced\">announced</a> in August a definitive agreement with Thoma Bravo to become a privately held company. Under the terms of the agreement, stockholders are set to receive $70.00 per share in cash.</p>\n<p>Dayforce (<a href=\"https://seekingalpha.com/symbol/DAY\" title=\"Dayforce Inc.\">DAY</a>) investors are set to vote on the deal at a meeting on Nov. 12. </p>\n<p> </p>\n</body></html>",
            "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
            "link": "https://seekingalpha.com/news/4512469-dayforce-holders-should-vote-in-favor-of-sale-to-thoma-bravo-iss-says",
            "pub_date": "2025-11-01 00:30:58",
            "source": "seekalpha",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "4512334",
            "title": "Wall Street trades mixed despite Amazon's rally",
            "description": "<html><body><p>Wall Street was mixed on Friday despite upbeat earnings from big tech companies.</p>\n<p>Rising the most on the session was the tech focused Nasdaq Composite (<span class=\"ticker-hover-wrapper\"><span class=\"ticker-hover-wrapper\"><span class=\"ticker-hover-wrapper\"><span class=\"ticker-hover-wrapper\"><span class=\"ticker-hover-wrapper\"><span class=\"ticker-hover-wrapper\"><span class=\"ticker-hover-wrapper\"><span class=\"ticker-hover-wrapper\"><span class=\"ticker-hover-wrapper\"><a href=\"https://seekingalpha.com/symbol/COMP:IND\" title=\"NASDAQ Composite Index\">COMP:IND</a></span></span></span></span></span></span></span></span></span>) which was last up <span style=\"color: #008000;\">0.4%</span>. At the same time, the benchmark S&amp;P 500 (<a href=\"https://seekingalpha.com/symbol/SP500\" title=\"S&amp;P 500 Index\">SP500</a>) was in the green by <span style=\"color: #008000;\">0.1%</span>, and the blue-chip Dow (<span class=\"ticker-hover-wrapper\"><span class=\"ticker-hover-wrapper\"><span class=\"ticker-hover-wrapper\"><span class=\"ticker-hover-wrapper\"><span class=\"ticker-hover-wrapper\"><span class=\"ticker-hover-wrapper\"><span class=\"ticker-hover-wrapper\"><span class=\"ticker-hover-wrapper\"><span class=\"ticker-hover-wrapper\"><a href=\"https://seekingalpha.com/symbol/DJI\" title=\"Dow Jones Industrial Average Index\">DJI</a></span></span></span></span></span></span></span></span></span>) dipped <span style=\"color: #ff0000;\">0.1%</span>.</p>\n<p>From a sector point of view, three of the 11 S&amp;P segments advanced with Consumer Discretionary leading the way. At the other end of the spectrum, the Utilities space has suffered the most on the session so far.</p>\n<p>U.S. Treasury yields ticked lower with the longer-end U.S. 10-year Treasury yield (<a href=\"https://seekingalpha.com/symbol/US10Y\" title=\"United States 10-Year Bond Yield\">US10Y</a>) falling 1 basis point to 4.08% and the shorter-end U.S. 2-year Treasury yield (<a href=\"https://seekingalpha.com/symbol/US2Y\" title=\"United States 2-Year Bond Yield\">US2Y</a>) moved down by 1 basis point to 3.60%.</p>\n<p>\"Indeed, just as the tech mood had soured yesterday, this morning that has mostly turned around following results from Apple and Amazon after the closing bell,\" Deutsche Bank's Jim Reid said.</p>\n<p>Amazon (<a href=\"https://seekingalpha.com/symbol/AMZN\" title=\"Amazon.com, Inc.\">AMZN</a>) soared <span style=\"color: #008000;\">10.1%</span> after it <a href=\"https://seekingalpha.com/news/4511697-amazon-surges-after-q3-beat-driven-by-aws-ad-growth-offsetting-margin-pressures#hasComeFromMpArticle\" target=\"_blank\" title=\"topped\">topped</a> Q3 estimates with better-than-expected net sales, profits, and subscription revenues, and more importantly. It also delivered a beat on the company’s AWS, all of which offset compressed margins.</p>\n<p>Apple (<a href=\"https://seekingalpha.com/symbol/AAPL\" title=\"Apple Inc.\">AAPL</a>) traded near even after the tech giant <a href=\"https://seekingalpha.com/news/4511434-apple-slips-as-iphone-china-sales-fall-short-in-q4#hasComeFromMpArticle\" target=\"_blank\" title=\"reported\">reported</a> fiscal fourth-quarter results that topped estimates.</p>\n<p>On political news, the U.S. States reportedly <a href=\"https://seekingalpha.com/news/4512097-trump-putin-summit-canceled-after-moscow-sends-memo-to-washington---ft#hasComeFromMpArticle\" target=\"_blank\" title=\"cancelled\">cancelled</a> a planned Budapest summit between President Donald Trump and Russian President Vladimir Putin following Russia's firm stance on hardline demands regarding Ukraine.</p>\n<p>As for other stocks that are on the move, shares of First Solar (<a href=\"https://seekingalpha.com/symbol/FSLR\" title=\"First Solar, Inc.\">FSLR</a>) have jumped up by <span style=\"color: #008000;\">13.2%</span>, while shares of DexCom (<a href=\"https://seekingalpha.com/symbol/DXCM\" title=\"DexCom, Inc.\">DXCM</a>) plunged <span style=\"color: #ff0000;\">15.1%</span>.</p>\n</body></html>",
            "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
            "link": "https://seekingalpha.com/news/4512334-wall-street-dow-sp500-nasdaq",
            "pub_date": "2025-11-01 00:25:56",
            "source": "seekalpha",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "4512481",
            "title": "Sumitomo Pharma Co, Ltd. GAAP EPS of JPY 248.84, revenue of JPY 227.12B",
            "description": "<html><body><ul>\n<li>Sumitomo Pharma Co., Ltd. <a href=\"https://www.sumitomo-pharma.com/news/assets/pdf/ebr20251031.1.pdf\" rel=\"nofollow\" target=\"_blank\">press release</a>  (SMDPY): 1H  GAAP EPS of JPY 248.84.</li>\n<li>Revenue of JPY 227.12B.</li>\n</ul>\n</body></html>",
            "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
            "link": "https://seekingalpha.com/news/4512481-sumitomo-pharma-co-ltd-gaap-eps-of-jpy-24884-revenue-of-jpy-22712b",
            "pub_date": "2025-11-01 00:25:56",
            "source": "seekalpha",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "4512477",
            "title": "Alps Alpine reports Q2 results",
            "description": "<html><body><ul>\n<li>Alps Alpine <a href=\"https://ssl4.eir-parts.net/doc/6770/ir_material_for_fiscal_ym4/189673/00.pdf\" rel=\"nofollow\" target=\"_blank\">press release</a>  (APELY): Q2 Profit Attributable to Owners of Parent of ¥ 16.1B.</li>\n<li>Revenue of ¥ 266.7B.</li>\n</ul>\n</body></html>",
            "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
            "link": "https://seekingalpha.com/news/4512477-alps-alpine-reports-q2-results",
            "pub_date": "2025-11-01 00:20:57",
            "source": "seekalpha",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "4512479",
            "title": "Aker Solutions GAAP EPS of NOK 1.79, revenue of NOK 17B",
            "description": "<html><body><ul>\n<li>Aker Solutions <a href=\"https://seekingalpha.com/pr/20287800-aker-solutions-asa-third-quarter-results-2025\">press release</a>  (AKRTF): Q3  GAAP EPS of NOK 1.79.</li>\n<li>Revenue of NOK 17B.</li>\n</ul>\n</body></html>",
            "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
            "link": "https://seekingalpha.com/news/4512479-aker-solutions-gaap-eps-of-nok-179-revenue-of-nok-17b",
            "pub_date": "2025-11-01 00:20:57",
            "source": "seekalpha",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "4512439",
            "title": "Gene editing therapy companies rise on word of streamlined FDA approval process",
            "description": "<html><body><ul>\n<li>Companies focused on gene editing therapies, including CRISPR Therapeutics (<span class=\"ticker-hover-wrapper\"><span class=\"ticker-hover-wrapper\"><span class=\"ticker-hover-wrapper\"><span class=\"ticker-hover-wrapper\"><a href=\"https://seekingalpha.com/symbol/CRSP\" title=\"CRISPR Therapeutics AG\">CRSP</a></span></span></span></span>), Editas Medicines (<span class=\"ticker-hover-wrapper\"><a href=\"https://seekingalpha.com/symbol/EDIT\" title=\"Editas Medicine, Inc.\">EDIT</a></span>), and Intellia Therapeutics (<span class=\"ticker-hover-wrapper\"><a href=\"https://seekingalpha.com/symbol/NTLA\" title=\"Intellia Therapeutics, Inc.\">NTLA</a></span>) are trading higher Friday following a report that the US FDA will make it easier for these medicines to gain approval.</li>\n<li>In an interview with <em>Bloomberg</em>, Vinay Prasad, director of the agency's Center for Biologics and Research, said, \"Regulation has to evolve as fast as science evolves,\" adding the FDA is \"going to be extremely flexible and work very fast with the scientists who want to bring these therapies to kids who need it.\"</li>\n<li>Prasad <a href=\"https://www.bloomberg.com/news/articles/2025-10-31/fda-clears-way-for-faster-personalized-gene-editing-treatments\" rel=\"nofollow\" target=\"_blank\" title=\"intends to outline\">intends to outline</a> in early November how a streamlined pathway for gene editing therapy approvals would work, adding that the paper will serve to boost investment in the gene editing space.</li>\n<li>A separate paper published Friday in <em><a href=\"https://www.cell.com/action/showPdf?pii=S0002-9297%2825%2900397-0\" rel=\"nofollow\" target=\"_blank\" title=\"The American Journal of Human Genetics\">The American Journal of Human Genetics</a></em> on how clinical trials can be conducted so that a single trial of several genetic disorders can be conducted rather than separate ones for each condition.</li>\n</ul>\n</body></html>",
            "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
            "link": "https://seekingalpha.com/news/4512439-gene-editing-therapy-companies-rise-word-streamlined-fda-approval-process",
            "pub_date": "2025-11-01 00:15:47",
            "source": "seekalpha",
            "kind": 1,
            "language": "en"
        }
    ]
}